

GUIDELINES FOR THE PREVENTION OF CHEMOTHERAPY REGIMEN SPECIFIC COMPLICATIONS – SERIOUS HYPERSENSITIVITY REACTIONS

INTRODUCTION

The drugs in the following table are known to cause allergic reactions. The list is not exhaustive. Refer to individual SACT (systemic anticancer therapy) protocols and Summary of Product Characteristics for further details.

Note: any individual may react to any drug or excipient.

DRUGS KNOWN TO CAUSE HYPERSENSITIVITY REACTIONS

Drug	Common Reactions	Routine Pre-Medication Required	Notes
Antithymocyte globulins	Fever Skin reactions	Paracetamol Chlorphenamine	Rabbit derived: Thymoglobuline® Horse derived: Atgam®
Asparaginase	Rash Anaphylaxis	None	<i>Escherichia coli</i> derived: Pegaspargase® <i>Erwinia chrysanthemi</i> derived: Erwinase®
Bleomycin	Fever Respiratory complications	None	
Blinatumomab	Fever Infusion related reactions Cytokine release syndrome	Paracetamol Dexamethasone	Bispecific T-cell receptor-engaging (BiTE) antibody
Brentuximab vedotin	Infusion related reactions	Paracetamol Dexamethasone Chlorphenamine	Antibody-drug conjugate Monoclonal antibody produced by recombinant DNA technology in Chinese Hamster ovary cells
Carboplatin/ Cisplatin	Late onset rash Re-challenge may lead to bronchospasm or anaphylaxis	None	
Carmustine	Flushing of the skin and conjunctiva	None	Reactions due to alcohol content of product
Cytarabine	Fever Rash	None	
Dinutuximab beta	Infusion related reactions Cytokine release syndrome Anaphylaxis	Paracetamol Chlorphenamine	Mouse-human chimeric monoclonal antibody produced in Chinese Hamster ovary cells
Docetaxel	Hypotension Bronchospasm Rash Fluid retention	Dexamethasone	
Etoposide	Rash Anaphylaxis Bronchospasm	None	

Drug	Common Reactions	Routine Pre-Medication Required	Notes
Inotuzumab ozogamicin	Hypotension Flushes Breathing problems	Paracetamol Hydrocortisone Chlorphenamine	Antibody-drug conjugate Recombinant humanised monoclonal antibody
Mifamurtide	Fever Chills	Paracetamol (routine use of corticosteroids should be avoided)	Synthetic analogue of muramyl dipeptide, an immune stimulatory component of <i>Mycobacterium sp.</i> cell walls
Procarbazine	Skin reactions	None	Procarbazine is a weak monoamine oxidase inhibitor – mild monoamine oxidase reactions reported with tyramine containing foods
Rituximab	Fever Chills Cytokine release syndrome	Paracetamol Chlorphenamine	Mouse-human chimeric monoclonal antibody produced in Chinese Hamster ovary cells

PRE-MEDICATION

To prevent serious hypersensitivity reactions pre-medication must be prescribed, if indicated. Refer to specific guidance in relevant clinical guideline or SACT protocol.

ANAPHYLAXIS

Refer to C23-Resuscitation Policy (Anaphylaxis Algorithm).

**GUIDELINES FOR THE PREVENTION OF CHEMOTHERAPY REGIMEN SPECIFIC
COMPLICATIONS – SERIOUS HYPERSENSITIVITY REACTIONS**

Version:	1
Ratified by:	Medicines Management and Optimisation Committee (MMOC)
Date ratified:	17 th March 2021
Name of originator/author:	Liz Evans (Oncology Pharmacist)
Name of responsible committee:	Chemotherapy Group
Name of executive sponsor:	N/A
Key search words:	Guidelines, chemotherapy, chemo, hypersensitivity, SACT, Oncology
Date issued:	23 rd April 2021
Review date:	March 2024

Version Control Table

Version	Date	Author(s)	Status	Comment(s)
1	Mar 21	Liz Evans	Current	

Review and Revision(s) Log

Record of revision(s) made to guidelines since Version 1

Section Number	Page Number	Revision(s) made	Reason for revision(s)
All		Guidance on hypersensitivity removed from Cytotoxic Policy	To keep guidelines and policy separate